ANP-230 is a state-independent selective inhibitor of sodium channels Nav1.7, 1.8, and 1.9 (IC50s respectively: 7.1 µM, 11.4 µM, and 6.7 µM).1 Selective over the cardiac Nav1.5 channel (IC50 = 156 µm). It potently reduced neuronal excitability in rat DRG neurons.3 ANP-230 reduced pain sensitivity in a mouse episodic pain syndrome model.2 It demonstrated efficacy in several models of neuropathic and inflammatory pain with no motor function impairment.3 It also potentiated the anti-allodynic effects of pregabalin and morphine when administered concurrently.3
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
